aTyr Pharma Aktie - ATYR

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

3,18

Gebot

3,18

Fragen

3,24

Volumen

537

0,00 Tagesbereich 0,00

1,42 52-Wochen-Bereich 4,66

Handelsende

3,10

Handelsbeginn

Letzte Trade

100

3.18

(formt)

Letzter Handelszeitpunkt

11:58:59

Durchschnittliches Volumen (3 Mio.)

1.168.231

Finanzvolumen

VWAP

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a...

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage...

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology...

Form 4 - Statement of changes in beneficial ownership of securities

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.02	0.632911392405	3.16	3.725	2.705	2073198	3.16594345	CS
4	-0.57	-15.2	3.75	4.66	2.705	1766555	3.67754806	CS
12	-0.05	-1.5479876161	3.23	4.66	2.705	1168231	3.64531986	CS
26	1.3	69.1489361702	1.88	4.66	1.68	1017164	3.24086594	CS
52	1.43	81.7142857143	1.75	4.66	1.42	792507	2.99985258	CS
156	1.43	81.7142857143	1.75	4.66	1.42	792507	2.99985258	CS
260	1.43	81.7142857143	1.75	4.66	1.42	792507	2.99985258	CS

ATYR - Frequently Asked Questions (FAQ)

What is the current aTyr Pharma share price?

The current share price of aTyr Pharma is US$ 3,18

What is the 1 year trading range for aTyr Pharma share price?

aTyr Pharma has traded in the range of US$ 1,42 to US$ 4,66 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
AWHAspira Womans Health Inc	US$ 0,3716 (87,68%)	76,99M
TSVT2seventy bio Inc	US$ 4,925 (75,89%)	1,12M
CUTRCutera Inc	US$ 0,1924 (49,73%)	33,94M
SNOASonoma Pharmaceuticals Inc	US$ 4,09 (46,59%)	17,33M
TNONTenon Medical Inc	US$ 1,78 (42,40%)	12,25M
MBXMBX Biosciences Inc	US$ 5,01 (-44,21%)	2
ARVNArvinas Inc	US$ 10,85 (-38,21%)	263,44k
JANXJanux Therapeutics Inc	US$ 20,05 (-33,65%)	40
SVRASavara Inc	US$ 2,01 (-24,44%)	4
SNCRSynchronoss Technologies Inc	US$ 6,01 (-22,45%)	4
AWHAspira Womans Health Inc	US$ 0,3716 (87,68%)	76,99M
CUTRCutera Inc	US$ 0,1924 (49,73%)	33,94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 7,77 (5,28%)	22,95M
SNOASonoma Pharmaceuticals Inc	US$ 4,09 (46,59%)	17,33M
BTOGBit Origin Ltd	US$ 0,4837 (1,81%)	15,09M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

aTyr Pharma Inc (ATYR)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

ATYR Neueste Nachrichten

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ATYR - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

aTyr Pharma Inc (ATYR) Börsenkurse

aTyr Pharma Inc (ATYR)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

ATYR Neueste Nachrichten

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ATYR - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen